Graft vs Host Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034
The 7 major Graft vs Host Disease markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 6.2 Billion by 2034, exhibiting a growth rate (CAGR) of 14.6% during 2024-2034.
The Graft vs Host Disease Market has been comprehensively analyzed in IMARC's new report titled "Graft vs Host Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast". Graft versus host disease (GvHD) refers to a condition that can occur after an allogeneic transplant. GvHD develops when donated bone marrow or peripheral blood stem cells perceive the recipient's body as foreign and attack the body. Acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD) are the two main types of GvHD. Acute and chronic GvHD both have modest to severe symptoms. Acute GvHD typically manifests within a few days or even up to six months following a transplant. The most afflicted organs are the skin, liver, intestines, and immune system. Jaundice (yellowing of the skin or eyes) or other liver disorders, skin rash, itching, and redness on specific parts of the skin are examples of common acute symptoms. A lifetime of chronic GvHD is possible and typically begins more than three months following a transplant. Chronic symptoms may include dry eyes, burning sensation, vision changes, white patches inside the mouth, dry mouth, sensitivity to spicy foods, fatigue, muscle weakness, chronic pain, etc. GvHD diagnosis can be challenging and include several procedures and tests, although GvHD can often be identified only by symptoms. The tests most frequently used to confirm GvHD include skin, gastrointestinal, liver, and lung biopsies.
The increasing prevalence of blood cancer along with the inflating number of bone marrow transplants to treat such condition is primarily driving the graft vs host disease market. In addition to this, the widespread adoption of corticosteroids as a front-line therapy owing to their proven safety and efficacy is also bolstering the market growth. Moreover, several key players are making significant R&D investments in developing biological and patented small-molecule immunosuppressive therapies that are tailored to conditioning and transplant type. This, in turn, is further acting as a significant growth-inducing factor. Besides this, the ongoing development of novel therapeutic approaches that are aimed at targeting T-cell responses or signaling pathways is also creating a positive outlook for the market. Additionally, the emerging popularity of extracorporeal photopheresis, a leukapheresis-therapeutical approach that works by altering the function of lymphocytes in the blood, for treating the ailment is further augmenting the market growth. Apart from this, the introduction of innovative drug candidates that aid in overcoming the steroid resistance associated with the disease is also expected to drive the graft vs host disease market in the coming years.
IMARC Group's new report "Graft vs Host Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Graft vs Host Disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Graft vs Host Disease market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Graft vs Host Disease across the seven major markets. According to the report the United States has the largest patient pool for Graft vs Host Disease and also represents the largest market for Graft vs Host Disease treatment. Furthermore, the current Graft vs Host Disease treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Graft vs Host Disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Graft vs Host Disease Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Graft vs Host Disease Market
Sales of Various Drugs Across the Graft vs Host Disease Market
Reimbursement Scenario in the Graft vs Host Disease Market
In-Market and Pipeline Drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Graft vs Host Disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Graft vs Host Disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Graft vs Host Disease market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Graft vs Host Disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Graft vs Host Disease market?
Epidemiology Insights
What is the size of the Graft vs Host Disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Graft vs Host Disease across the seven major markets?
What are the key factors driving the epidemiological trend of Graft vs Host Disease?
What will be the growth rate of Graft vs Host Disease patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Graft vs Host Disease drugs and what are their market performance?
What are the key pipeline Graft vs Host Disease drugs and how are they expected to perform in the coming years?
How safe are the current marketed Graft vs Host Disease drugs and what are their efficacies?
How safe are the late-stage pipeline Graft vs Host Disease drugs and what are their efficacies?
What are the current treatment guidelines for Graft vs Host Disease drugs across the seven major markets?
Who are the key companies in the Graft vs Host Disease market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Graft vs Host Disease market?
The Graft vs Host Disease Market has been comprehensively analyzed in IMARC's new report titled "Graft vs Host Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast". Graft versus host disease (GvHD) refers to a condition that can occur after an allogeneic transplant. GvHD develops when donated bone marrow or peripheral blood stem cells perceive the recipient's body as foreign and attack the body. Acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD) are the two main types of GvHD. Acute and chronic GvHD both have modest to severe symptoms. Acute GvHD typically manifests within a few days or even up to six months following a transplant. The most afflicted organs are the skin, liver, intestines, and immune system. Jaundice (yellowing of the skin or eyes) or other liver disorders, skin rash, itching, and redness on specific parts of the skin are examples of common acute symptoms. A lifetime of chronic GvHD is possible and typically begins more than three months following a transplant. Chronic symptoms may include dry eyes, burning sensation, vision changes, white patches inside the mouth, dry mouth, sensitivity to spicy foods, fatigue, muscle weakness, chronic pain, etc. GvHD diagnosis can be challenging and include several procedures and tests, although GvHD can often be identified only by symptoms. The tests most frequently used to confirm GvHD include skin, gastrointestinal, liver, and lung biopsies.
The increasing prevalence of blood cancer along with the inflating number of bone marrow transplants to treat such condition is primarily driving the graft vs host disease market. In addition to this, the widespread adoption of corticosteroids as a front-line therapy owing to their proven safety and efficacy is also bolstering the market growth. Moreover, several key players are making significant R&D investments in developing biological and patented small-molecule immunosuppressive therapies that are tailored to conditioning and transplant type. This, in turn, is further acting as a significant growth-inducing factor. Besides this, the ongoing development of novel therapeutic approaches that are aimed at targeting T-cell responses or signaling pathways is also creating a positive outlook for the market. Additionally, the emerging popularity of extracorporeal photopheresis, a leukapheresis-therapeutical approach that works by altering the function of lymphocytes in the blood, for treating the ailment is further augmenting the market growth. Apart from this, the introduction of innovative drug candidates that aid in overcoming the steroid resistance associated with the disease is also expected to drive the graft vs host disease market in the coming years.
IMARC Group's new report "Graft vs Host Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Graft vs Host Disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Graft vs Host Disease market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Graft vs Host Disease across the seven major markets. According to the report the United States has the largest patient pool for Graft vs Host Disease and also represents the largest market for Graft vs Host Disease treatment. Furthermore, the current Graft vs Host Disease treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Graft vs Host Disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Graft vs Host Disease Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Graft vs Host Disease Market
Sales of Various Drugs Across the Graft vs Host Disease Market
Reimbursement Scenario in the Graft vs Host Disease Market
In-Market and Pipeline Drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Graft vs Host Disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Graft vs Host Disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Graft vs Host Disease market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Graft vs Host Disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Graft vs Host Disease market?
Epidemiology Insights
What is the size of the Graft vs Host Disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Graft vs Host Disease across the seven major markets?
What are the key factors driving the epidemiological trend of Graft vs Host Disease?
What will be the growth rate of Graft vs Host Disease patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Graft vs Host Disease drugs and what are their market performance?
What are the key pipeline Graft vs Host Disease drugs and how are they expected to perform in the coming years?
How safe are the current marketed Graft vs Host Disease drugs and what are their efficacies?
How safe are the late-stage pipeline Graft vs Host Disease drugs and what are their efficacies?
What are the current treatment guidelines for Graft vs Host Disease drugs across the seven major markets?
Who are the key companies in the Graft vs Host Disease market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Graft vs Host Disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GRAFT VS HOST DISEASE - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 GRAFT VS HOST DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GRAFT VS HOST DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 GRAFT VS HOST DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Graft vs Host Disease Guidelines, Management and Treatment
8.2 Graft vs Host Disease Treatment Algorithm
9 GRAFT VS HOST DISEASE - UNMET NEEDS
10 GRAFT VS HOST DISEASE - KEY ENDPOINTS OF TREATMENT
11 GRAFT VS HOST DISEASE - MARKETED PRODUCTS
11.1 List of Graft vs Host Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Imbruvica (ibrutinib) - Janssen/Pharmacyclics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Jakafi (Ruxolitinib) - Incyte Corporation/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Orencia (Abatacept) - Bristol-Myers Squibb
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Rezurock (Belumosudil) - Kadmon Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 GRAFT VS HOST DISEASE - PIPELINE DRUGS
12.1 List of Graft vs Host Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Alzumab (Itolizumab) - Biocon/Equillium
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Axatilimab - Syndax Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ASC930 - ASC Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Itacitinib - Incyte Corporation
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MC 0518 - Medac
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. GRAFT VS HOST DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 GRAFT VS HOST DISEASE - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Graft vs Host Disease - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Graft vs Host Disease - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Graft vs Host Disease - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Graft vs Host Disease - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Graft vs Host Disease - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Graft vs Host Disease - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Graft vs Host Disease - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Graft vs Host Disease - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Graft vs Host Disease - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Graft vs Host Disease - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Graft vs Host Disease - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Graft vs Host Disease - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Graft vs Host Disease - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Graft vs Host Disease - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Graft vs Host Disease - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Graft vs Host Disease - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Graft vs Host Disease - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Graft vs Host Disease - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Graft vs Host Disease - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Graft vs Host Disease - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Graft vs Host Disease - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Graft vs Host Disease - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Graft vs Host Disease - Access and Reimbursement Overview
15 GRAFT VS HOST DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 GRAFT VS HOST DISEASE MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GRAFT VS HOST DISEASE - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 GRAFT VS HOST DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GRAFT VS HOST DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 GRAFT VS HOST DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Graft vs Host Disease Guidelines, Management and Treatment
8.2 Graft vs Host Disease Treatment Algorithm
9 GRAFT VS HOST DISEASE - UNMET NEEDS
10 GRAFT VS HOST DISEASE - KEY ENDPOINTS OF TREATMENT
11 GRAFT VS HOST DISEASE - MARKETED PRODUCTS
11.1 List of Graft vs Host Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Imbruvica (ibrutinib) - Janssen/Pharmacyclics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Jakafi (Ruxolitinib) - Incyte Corporation/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Orencia (Abatacept) - Bristol-Myers Squibb
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Rezurock (Belumosudil) - Kadmon Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 GRAFT VS HOST DISEASE - PIPELINE DRUGS
12.1 List of Graft vs Host Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Alzumab (Itolizumab) - Biocon/Equillium
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Axatilimab - Syndax Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ASC930 - ASC Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Itacitinib - Incyte Corporation
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MC 0518 - Medac
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. GRAFT VS HOST DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 GRAFT VS HOST DISEASE - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Graft vs Host Disease - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Graft vs Host Disease - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Graft vs Host Disease - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Graft vs Host Disease - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Graft vs Host Disease - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Graft vs Host Disease - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Graft vs Host Disease - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Graft vs Host Disease - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Graft vs Host Disease - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Graft vs Host Disease - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Graft vs Host Disease - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Graft vs Host Disease - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Graft vs Host Disease - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Graft vs Host Disease - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Graft vs Host Disease - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Graft vs Host Disease - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Graft vs Host Disease - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Graft vs Host Disease - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Graft vs Host Disease - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Graft vs Host Disease - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Graft vs Host Disease - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Graft vs Host Disease - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Graft vs Host Disease - Access and Reimbursement Overview
15 GRAFT VS HOST DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 GRAFT VS HOST DISEASE MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
